-
Mashup Score: 7The Breast - 1 month(s) ago
x De-escalation of loco-regional treatment in breast cancer: Time to find the balance? Edited by Oreste Gentilini, Philip Poortmans, Maria João Cardoso, Elzbieta Senkus-Konefka Breast cancer management has improved hugely over the last 3 decades. Following its increasing complexity, close multi- and interdisciplinary working relations between all specialists involved in breast cancer diagnosis and treatment within structured Breast Units are now being considered a mandatory condition. In fact, the
Source: www.thebreastonline.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6The Breast - 2 month(s) ago
x De-escalation of loco-regional treatment in breast cancer: Time to find the balance? Edited by Oreste Gentilini, Philip Poortmans, Maria João Cardoso, Elzbieta Senkus-Konefka Breast cancer management has improved hugely over the last 3 decades. Following its increasing complexity, close multi- and interdisciplinary working relations between all specialists involved in breast cancer diagnosis and treatment within structured Breast Units are now being considered a mandatory condition. In fact, the
Source: www.thebreastonline.comCategories: General Medicine News, Onc News and JournalsTweet-
New special issue published in The Breast: De-escalation of loco-regional treatment in breast cancer: Time to find the balance? https://t.co/Q1DmUVyEpr 1/3
-
-
Mashup Score: 412023 Year in review: Early breast cancer - 2 month(s) ago
The results of several studies aiming to tailor early breast cancer treatment to individual risk were released in 2023. Axillary lymph node dissections and radiotherapy may be safely omitted in carefully selected patients. Sustained benefit from adjuvant CDK4/6 inhibitors was observed in high-risk hormone receptor-positive disease and the addition of immunotherapy to neoadjuvant chemotherapy improved pathological response. Continued benefit from perioperative pembrolizumab was reported in patients with triple negative breast cancer, while atezolizumab did not improve the risk of recurrence either pre- or postoperatively.
Source: www.thebreastonline.comCategories: General Medicine News, Hem/OncsTweet-
RT @dr_yakupergun: 2023 Year in review: Early breast cancer #bcsm https://t.co/ACZMy6EOa9 https://t.co/q2u1TIjgtb
-
-
Mashup Score: 29Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data - 4 month(s) ago
Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life.The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received: abiraterone acetate (62 %), enzalutamide (8 %) and bicalutamide (30 %). CBR at 6 months was 29 % (7/24) with 2 CR, 3 PR and 2 SD. Four patients had a clinical benefit >12 months. Real-life efficacy of AA use in metastatic AR + TNBC are in line with data from published trials.
Source: www.thebreastonline.comCategories: General Medicine News, Hem/OncsTweet-
Retro French analysis further defining efficacy of this Rx for AR+ TNBC. @TheBreastOnline Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data - The Breast https://t.co/ZBZUR2x1li
-
-
Mashup Score: 6Regularly scheduled physical examinations and the detection of breast cancer recurrences - 7 month(s) ago
Follow-up care of early breast cancer (EBC) patients usually includes routinely scheduled physical examinations. While ASCO guidelines recommend a physical exam every three to six months for the first three years, little evidence supports this schedule. We evaluated recurrence detection of patients transferred into a single centre survivorship program that follows ASCO recommendations.
Source: www.thebreastonline.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Interesting assessment of regular PE in detecting local and distance recurrence - doesnt work! ~35,000 exams required to detect 2! Time to rethink guidelines? Regularly scheduled PEs and detection of BC recurrences - The Breast https://t.co/AdkdAxMxOe @oncoalert @TheBreastOnline
-
-
Mashup Score: 0Home Page: The Breast - 4 year(s) ago
…
Source: www.thebreastonline.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Have you considered publishing your next paper in The Breast? Authors submitting to The Breast receive a first decision within an average of 2.75 weeks. Find out more https://t.co/m5Mx5COm66 #ESMOBreast20 https://t.co/BMAjzQZLj6
-
-
Mashup Score: 0Home Page: The Breast - 4 year(s) ago
…
Source: www.thebreastonline.comCategories: Hem/Onc News and JournalsTweet-
(3/3) Find out more today https://t.co/rF3WrOY0xL https://t.co/YSKkPosivr
-
New special issue published in The Breast: De-escalation of loco-regional treatment in breast cancer: Time to find the balance? https://t.co/Q1DmUVyEpr 1/3